Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13698539 | 0.77 | MAPT (0.48) | MEN1KMT2AALDH1A1L3MBTL1KDM4E | |
| SCHEMBL12550197 | 0.75 | MEN1 (0.62) | MEN1KMT2AHSD11B1POLB | |
| SCHEMBL3218831 | 0.74 | ALDH1A1 (0.56) | MEN1KMT2ARAB9AMAPK1ALDH1A1 | |
| SCHEMBL494192 | 0.72 | KDM4E (0.74) | MEN1KMT2ARAB9AMAPK1ALDH1A1 | |
| SCHEMBL14847757 | 0.72 | RAB9A (0.55) | RAB9AMAPK1HSD11B1L3MBTL1KDM4E | |
| SCHEMBL8049609 | 0.71 | RAB9A (0.85) | MEN1KMT2ARAB9AMAPK1L3MBTL1 | |
| SCHEMBL493045 | 0.71 | POLB (0.72) | MEN1KMT2ARAB9AMAPK1ALDH1A1 | |
| SCHEMBL3205229 | 0.70 | HTR6 (0.50) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL27979614 | 0.70 | KDM4E (0.50) | MEN1KMT2AALDH1A1HSD11B1KDM4E | |
| SCHEMBL14829559 | 0.70 | RAB9A (0.52) | MEN1KMT2ARAB9AMAPK1HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | MEN1 1354/4885KMT2A 1609/4885RAB9A 3470/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | MEN1 1687/4885KMT2A 1591/4885RAB9A 3846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.